Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

A study of clozapine and long-term hospitalisation rates

View through CrossRef
Aims and MethodThe aim of the study was to investigate the use of clozapine in treatment-resistant schizophrenia and its impact on hospitalisation rates when prescribed in accordance with National Institute for Clinical Excellence (NICE) guidelines. Case records were examined of patients admitted to the psychiatric unit of Glan Clwyd Hospital between 1996 and 2001.ResultsOf 59 patients identified as having treatment-resistant schizophrenia, 83% had been considered for clozapine, 48% were taking clozapine, 20% had refused the drug and 15% had stopped taking it because of side-effects. The mean annual hospitalisation rate for patients receiving clozapine for a minimum of 3 years was 13.5 days, markedly lower than those not receiving this drug (34.0 days, P=0.03). Older patients were less likely to have been offered clozapine (P=0.006).Clinical ImplicationsThis study supports the NICE guidelines recommending clozapine for patients with treatment-resistant disease. Clozapine is offered less often to older patients; factors influencing this require investigation.
Title: A study of clozapine and long-term hospitalisation rates
Description:
Aims and MethodThe aim of the study was to investigate the use of clozapine in treatment-resistant schizophrenia and its impact on hospitalisation rates when prescribed in accordance with National Institute for Clinical Excellence (NICE) guidelines.
Case records were examined of patients admitted to the psychiatric unit of Glan Clwyd Hospital between 1996 and 2001.
ResultsOf 59 patients identified as having treatment-resistant schizophrenia, 83% had been considered for clozapine, 48% were taking clozapine, 20% had refused the drug and 15% had stopped taking it because of side-effects.
The mean annual hospitalisation rate for patients receiving clozapine for a minimum of 3 years was 13.
5 days, markedly lower than those not receiving this drug (34.
0 days, P=0.
03).
Older patients were less likely to have been offered clozapine (P=0.
006).
Clinical ImplicationsThis study supports the NICE guidelines recommending clozapine for patients with treatment-resistant disease.
Clozapine is offered less often to older patients; factors influencing this require investigation.

Related Results

Saliva Based Clozapine Therapeutic Drug Monitoring: A Systematic Review
Saliva Based Clozapine Therapeutic Drug Monitoring: A Systematic Review
ABSTRACTClozapine is superior in the treatment of treatment‐refractory schizophrenia but requires therapeutic drug monitoring (TDM) due to its unpredictable pharmacokinetics and do...
Solubility Enhancement of Clozapine Through Co-Crystal Formation with Isonicotinamide
Solubility Enhancement of Clozapine Through Co-Crystal Formation with Isonicotinamide
Clozapine (CLO) is an effective atypical antipsychotic to control the symptoms of psychosis and schizophrenia. Clozapine has low solubility and high permeability, so it is classifi...
Longitudinal Trend Evaluation and Prescription Cost Analysis (PCA) of Clozapine in the United Kingdom
Longitudinal Trend Evaluation and Prescription Cost Analysis (PCA) of Clozapine in the United Kingdom
AimsSevere Mental Illnesses (SMI) are a group of disorders which can have a debilitating impact on an individual's daily life functioning. The National Institute for Health and Car...
Case report: Time response of plasma clozapine concentrations on cessation of heavy smoking
Case report: Time response of plasma clozapine concentrations on cessation of heavy smoking
Smoking cessation in patients treated with clozapine might lead to elevated plasma concentrations and severe side effects. This case report investigated the trajectory of clozapine...
Clozapine Induced Pericarditis: A Systematic Review
Clozapine Induced Pericarditis: A Systematic Review
Aims: Clozapine is an atypical antipsychotic for treatment-resistant schizophrenia. Despite its efficacy, there are potential life-threatening side effects, including pericarditis,...

Back to Top